In the global race for GLP-1-based therapies for obesity and diabetes, Eli Lilly has aggressively gained market share since 2022 with its next-generation drug tirzepatide (marketed as Mounjaro/Zepbound), putting significant pressure on long-time leader Novo Nordisk. Rather than retreating, Novo Nordisk has mounted a strategic counteroffensive on multiple fronts: First, it accelerated production capacity for its oral semaglutide (Rybelsus) and high-dose injectable Wegovy to address persistent supply shortages. Second, the company doubled down on clinical evidence, continuously publishing long-term data demonstrating semaglutide’s benefits in cardiovascular and kidney protection, as well as weight loss, reinforcing its medical credibility. Third, Novo Nordisk is advancing next-generation multi-agonist candidates—such as CagriSema, a combination of semaglutide and an amylin analog—to challenge Lilly’s first-mover advantage with innovative pipeline assets. Additionally, the company is strengthening partnerships with U.S. healthcare payers, refining pricing strategies, and expanding into emerging markets. Despite Lilly’s strong momentum, Novo Nordisk’s deep expertise in diabetes care, robust manufacturing infrastructure, and global distribution network are helping it stabilize its position and prepare for renewed growth.
在GLP-1类减肥与糖尿病药物的全球竞争中，礼来（Eli Lilly）凭借其新一代药物Tirzepatide（商品名Mounjaro/Zepbound）自2022年起迅速抢占市场，对长期领先的诺和诺德（Novo Nordisk）形成强力压制。面对市场份额被蚕食、股价承压的局面，诺和诺德并未被动应对，而是通过三方面策略展开反攻：首先，加速推进其口服版司美格鲁肽（Rybelsus）及高剂量注射剂Wegovy的产能扩张，缓解长期供不应求的问题；其次，加大临床数据投入，持续发布司美格鲁肽在心血管、肾脏保护及减重方面的长期疗效证据，巩固其医学权威性；第三，积极布局下一代GLP-1/GIP双靶点甚至三靶点候选药物，如CagriSema（司美格鲁肽+Amylin类似物），以技术迭代应对礼来的先发优势。此外，诺和诺德还通过强化与美国医保体系的合作、优化定价策略以及拓展新兴市场，多维度提升竞争力。尽管礼来势头强劲，但诺和诺德凭借深厚的糖尿病治疗根基、强大的生产能力和全球分销网络，正逐步稳住阵脚并酝酿新一轮增长。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/5437.html